BioPharma Resources

Investigational drug · Phase 3

linsitinib

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Graves Orbitopathy, Thyroid Eye Disease, TED, Thyroid Eye Disease.

Phase 3

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

27

Any phase or sponsor naming "linsitinib"

First trial start

2023

Oct 11, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "linsitinib", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Graves Orbitopathy
  • Thyroid Eye Disease, TED
  • Thyroid Eye Disease
  • Endocrine System Diseases
  • Eye Diseases
  • Thyroid Associated Ophthalmopathy
  • Graves Ophthalmopathy
  • Thyroid Diseases
  • Orbital Diseases
  • Proptosis

Approved drugs for the same conditions: Endocrinology and women's health · Ophthalmology

Largest trials

Live from ClinicalTrials.gov: studies naming "linsitinib" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 155 on PubMed

Also in development for Graves Orbitopathy

  • LASN01Phase 22 trials

    Lassen Therapeutics 1 PTY LTD · Thyroid Eye Disease, Pulmonary Fibrosis, Graves Ophthalmopathy

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.